Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:986938.
doi: 10.1155/2014/986938. Epub 2014 Nov 27.

Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update

Paola Villafuerte-Gutierrez  1 , Lucia Villalon  2 , Juan E Losa  3 , Cesar Henriquez-Camacho  3
Affiliations
Review

Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update

Paola Villafuerte-Gutierrez et al. Adv Hematol. 2014.

Erratum in

Abstract

Febrile neutropenia is one of the most serious complications in patients with haematological malignancies and chemotherapy. A prompt identification of infection and empirical antibiotic therapy can prolong survival. This paper reviews the guidelines about febrile neutropenia in the setting of hematologic malignancies, providing an overview of the definition of fever and neutropenia, and categories of risk assessment, management of infections, and prophylaxis.

PubMed Disclaimer

References

    1. Freifeld A. G., Bow E. J., Sepkowitz K. A., Boeckh M. J., Ito J. I., Mullen C. A., Raad I. I., Rolston K. V., Young J. A. H., Wingard J. R. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clinical Infectious Diseases. 2011;52(4):e56–e93. doi: 10.1093/cid/cir073. - DOI - PubMed
    1. Keng M. K., Sekeres M. A. Febrile neutropenia in hematologic malignancies. Current Hematologic Malignancy Reports. 2013;8(4):370–378. doi: 10.1007/s11899-013-0171-4. - DOI - PubMed
    1. Goulenok T., Fantin B. Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations. Clinical Pharmacokinetics. 2013;52(10):869–883. doi: 10.1007/s40262-013-0086-1. - DOI - PubMed
    1. Pagano L., Caira M., Rossi G., Tumbarello M., Fanci R., Garzia M. G., Vianelli N., Filardi N., De Fabritiis P., Beltrame A., Musso M., Piccin A., Cuneo A., Cattaneo C., Aloisi T., Riva M., Rossi G., Salvadori U., Brugiatelli M., Sannicolò S., Morselli M., Bonini A., Viale P., Nosari A., Aversa F. A prospective survey of febrile events in hematological malignancies. Annals of Hematology. 2012;91(5):767–774. doi: 10.1007/s00277-011-1373-2. - DOI - PubMed
    1. de Naurois J., Novitzky-Basso I., Gill M. J., Marti F. M., Cullen M. H., Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology. 2010;21(5):v252–v256. doi: 10.1093/annonc/mdq196. - DOI - PubMed

LinkOut - more resources